Meaghan Smith News Today

Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease - Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research

FOSTER CITY - Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with...

- 19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead's Setting the P.A.C.E. Initiative -FOSTER CITY, CA / ACCESSWIRE / February 28, 2024 / Gilead Sciences, Inc. (NASDAQ:GILD) announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve...

* Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gileads Ongoing Commitment to Corporate Responsibility - * DJSI World Highlights the Most Sustainable...

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive ...

Gilead Sciences, Inc. announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Charlotte Cardin, The Glorious Sons and Tim Baker headline shows in Halifax this coming month.

– Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression –– Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first to market for these cancers –– Detailed...